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It is thought that the time interval between the antecedent pregnancy and diagnosis of gestational trophoblastic tumours (GTTs) may
influence the outcome of these patients. In this study, we investigate the significance of this time interval. Multivariate analysis was
used to investigate if the time interval was of prognostic significance from our cohort of 241 high-risk patients with GTT. Subsequent
cutpoint analysis was used to determine an optimal cutpoint for the interval covariate. The outcome of these patients was plotted
according to the Kaplan–Meier method. The time interval was of prognostic significance on multivariate analysis. A period of greater
than 2.8 years after pregnancy was found to be of most significance. The 5-year overall survival was 62.0% (95% CI: 47–76%) for
greater than 2.8 years vs 94% (95% CI: 91–97%) for less than 2.8 years (Po0.001). Multivariate analysis showed the presence of
liver metastasis and the number of metastasis was also of prognostic importance. The interval between antecedent pregnancy and
diagnosis in high-risk GTT is of prognostic significance. This gives some insight into the pathogenesis of the disease.
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Patients with gestational trophoblastic tumours (GTTs) are
stratified into low- and high-risk groups which have different
treatments and outcomes (Bagshawe, 1976; Kohorn, 2001; McNeish
et al, 2002). This stratification system was designed to identify
high-risk patients who were likely to require more intensive
combination chemotherapy. A number of factors, such as plasma
hCG level at presentation and the number of metastasis, are used
to stratify patients into these high- and low-risk groups. Each
factor scores numerical points. A score of 46 (FIGO score) or 48
(Charing Cross score) defines high-risk disease.
One of these factors is the interval between the antecedent
pregnancy and treatment, which if greater than 1 year scores 4 or
6 points in the FIGO or Charing Cross systems, respectively. The
reason for selecting the time interval of 1 year is unclear, although
it appears that tumour age in GTT is of prognostic significance
(Kim et al, 1998). Therefore, in this study, we investigate the
relationship between this time interval and outcome more closely.
PATIENTS AND METHODS
Data collection
The Charing Cross GTT database was screened to identify all
women diagnosed between 1984 and 2004. At presentation for
chemotherapy, patients were stratified into low- or high-risk
groups according to their Charing Cross score and treated
accordingly (Bagshawe, 1976; Kohorn, 2001; McNeish et al,
2002). Those patients scoring 9 or more were classed as high-
risk GTT and included in this study. These patients were treated in
similar manner using regimens according to protocol (Rustin et al,
1989; Newlands et al, 1998). Patients with placental site tumour
were excluded because the treatment and outcomes for these
patients is different (Papadopoulos et al, 2002).
This study was approved by our local Institutional Review
Board.
Statistical analysis
The interval between pregnancy and diagnosis was plotted as a
non-linear covariate in a univariate Cox regression using natural
splines. The resulting curve showed an increasing hazard ratio
with respect to interval. Cutpoint analysis was used to determine
an optimal cutpoint for the interval covariate. As the determina-
tion of a cutpoint may be unstable with respect to perturbations of
the data, this analysis was confirmed using non-parametric
bootstrapping, by repeating the original analysis 2000 times using
samples drawn from the original distribution with replacement.
Patients overall survival and disease-free survival was recorded
and plotted according to the Kaplan–Meier method.
Univariate and multivariate analysis was performed to identify
prognostic factors associated with outcome for patients with high-
risk disease. This was performed for high-risk patients using
initially the Charing cross scoring system and was repeated using
the FIGO scoring system to identify high-risk patients.
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The characteristics, treatment and outcome of the 241 patients are
shown in Table 1. In this study, all patients with a time period
of greater than 2.8 year group had previously histologically
confirmed GTT.
Cox regression univariate and multivariate analysis demon-
strated that the time interval between pregnancy and treatment for
GTT was of prognostic significance. This was true for high-risk
patients identified by either the WHO or FIGO scoring systems
(Po0.001 for both). The resulting hazard ratio from this data was
non-linear and rose with increased interval. Cutpoint analysis with
bootstrapping suggested that 2.8 years was the optimum cutoff
point (Figure 1a). The patients were subsequently separated into
two groups according to this time point. The characteristics and
outcome of patients in these two groups are compared in Table 1
and Figure 1b. Patients with an interval of greater than 2.8 years
had a significantly worse outcome (Table 1).
We subsequently went on to investigate the outcome of patients
with a time interval o1 and 1–2.8 years, this was because 1 year is
the current cutoff time point used for both scoring systems (Kim
et al, 1998). Results showed that this group of patients has a similar
outcome to patients with a time interval of less than 1 year (5-year
survival 94.4% (87.3–100% vs 93.8% (95% CI 90–97%), respec-
tively), but a better outcome compared to patients with a time
interval of greater than 2.8 years (62.0% (95% CI 47–76%): Po0.01).
Multivariate analysis showed three prognostic factors, which
independently predict the outcome of patients with high-risk
disease. These include an increased time interval between
antecedent pregnancy and diagnosis of high-risk disease (as
described earlier), the presence of liver metastasis at diagnosis and
more than eight metastasis at diagnosis. Other factors such as hCG
at presentation, age and the presence of lung metastasis were not
significant in multivariate analysis. Other possible confounding
factors such as a term pregnancy or ancedental pregnancy were not
found to be significant in multivariate analysis. Both the WHO
and FIGO scoring systems were significant for prognosis in using
univariate analysis. These scoring systems were precluded from the
multivariate analysis as they took into account a number of
potentially significant independent univariate factors.
DISCUSSION
These data show that an increased time interval between
pregnancy and diagnosis of GTT is associated with a worse
outcome. This appears particularly marked after 2.8 years.
The reason for excess mortality as the time interval increases
is unknown. Possible confounding factors are that patients with
a greater time interval may have more advanced disease at
Table 1 Patient characteristics
All patients
Less than
2.8 years since
pregnancy
Greater than
2.8 years since
pregnancy
Number 241 200 41
Median age 30 (range 17–61) 33 (range 17–54) 35 (range 22–61)
Median Prognostic
score (WHO).
11 (range 8–32) 11 (range 8–32) 14 (range 9–32)
Median Prognostic
score (FIGO).
8 (range 4–20) 8 (range 4–18) 9 (range 5–20)
Median follow-up 11.7 years 11.9 years 6.2 years
Range 0.1–23.8 Range 0.9–23.8 Range 0.1–23.8
Median HCG at
presentation
190000 200000 72000
300–3.4 million 300–3.3million 450–3.4million
Chemotherapy regimens
EMA/CO 206 (85%) 174 (87%) 32 (80%)
EP/EMA 14 (6%) 9 (5%) 5 (12%)
EMA/CNS 17 (7%) 14 (7%) 3 (7%)
Other 4 (1%) 3 (2%) 1 (1%)
Causal pregnancy
Term 125 (52%) 96 (48%) 29 (70%)
Abortion/unknown 37 (15%) 32 (16%) 6 (15%)
Molar 79 (33%) 73 (35%) 6 (15%)
Sites of metastasis
Pulmonary 98 (41%) 77 (39%) 21 (51%)
Extrapulmonary 38 (16%) 30 (15%) 8 (20%)
Both 26 (10%) 18 (9%) 8 (20%)
Deaths 27 (11%) 12 (6%) 15 (37%)
Cancer-related deaths 23 (10%) 10 (5%) 13 (32%)
5-year survival 87.4% 94.0% 62.0%
95% CI:
(77.8–96.8)
95% CI:
(91.3–97.0%)
(95% CI:
47.2–76.8%)
CI¼confidence interval; CNS¼central nervous system; EMA¼epithelial membrane
antigen; FIGO¼International Federation of Gynecologic and Obstetrics; WHO¼
World Health Organization.
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Figure 1 (A) Cutpoint analysis investigating the most significant time
point between pregnancy and diagnosis. (A) Interval vs coefficient for that
interval, used to derive the interval cutoff limit. Dotted lines show 95%
confidence intervals. Lower rug plot shows number of measurements at
each interval. (B) Comparison of patients with a time period of less and
more than 2.8 years since the antecedent pregnancy. Log rank Po0.0001.
Actuarial 5-year OS: 0–2.8 years¼94.0% (91–97%) 42.8 years¼62.0%
(47–76%).
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spresentation or be more likely to initially have a term pregnancy
(both associated with a worse prognosis). However, multivariate
analysis confirmed the time interval as an independent prognostic
factor.
Alternatively, these findings may occur because a longer interval
may be a consequence of slower tumour growth rates, allowing an
increase in the development of mutations, which are associated
with chemotherapy resistance in other tumour types (Kelland et al,
1992). Gestational trophoblastic tumour is the only cancer where
the date of the occurrence of the tumour is truly known, and this
extended period between occurrence and diagnosis being asso-
ciated with a poor outcome gives us some insight into the
pathogenesis this and perhaps other cancers.
Unlike previous studies of high risk GTT, these data exclude
all patients with placental site tumours, which has different
disease characteristics and should be considered as a separate
disease process (Papadopoulos et al, 2002). The exclusion of these
patients may account for the relatively good overall survival in this
series, compared with other published high-risk disease series
(Vaeth et al, 1984; Bower et al, 1997). It also allows us, for the
first time, to specifically investigate for prognostic factors in
these high-risk patients. Multivariate analysis showed that time
interval between pregnancy and diagnosis, liver metastasis
and greater than eight metastasis at diagnosis were associated
with poor prognosis. It is noteworthy that hCG at presenta-
tion, which is an important factor in separation between low- and
high-risk disease, is of no prognostic importance in high-risk
disease.
In summary, our findings suggest an increased time interval
pregnancy and diagnosis of GTT is of prognostic importance and
this gives us some insight into the pathogenesis of the disease. It
appears that a cut of 2.8 years is most significant. In view of the
poorer outcome of these patients, perhaps they should be
considered for more aggressive initial treatment.
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